Skip to main content

Avance Clinical Welcomes Alex Kavros as Executive Vice President of Scientific & Regulatory Affairs

By May 6, 2024Company News

Avance Clinical, a leading Contract Research Organization (CRO) renowned for its innovative solutions in the biotech industry, is excited to announce the appointment of Dr Alex Kavros as the new Executive Vice President of Global Scientific & Regulatory Affairs. With an impressive career spanning nearly two decades in drug development, regulatory science and operations, Alex brings a wealth of knowledge and experience to the Avance team.

Before joining Avance, Alex held significant roles at Ergomed, Worldwide Clinical Trials and Vifor Pharma, where he led clinical development campaigns, spearheaded global regulatory operations and optimized business processes and workflows . His expertise encompasses a broad range of pharmaceutical products, including biologics/ATMPs, small molecules and vaccines, across various stages of development from clinical development to marketing authorization and product launch.

Alex’s academic credentials are equally impressive, with a BSc (Hons) and PhD in Chemistry from Lancaster University, UK, followed by a Post-doc in Macromolecular Engineering at Carnegie Mellon University, Pittsburgh, PA. His robust scientific background   has been instrumental in his professional achievements and in shaping his approach to regulatory science.

In his previous roles, Alex has been a pivotal figure in driving business growth, enhancing regulatory service capabilities, and ensuring operational excellence and compliance within complex regulatory environments. His leadership in overseeing 5,000 regulatory submissions globally underscores his capability to manage and navigate the intricate regulatory landscape effectively.

Residing in Zurich, Switzerland, Alex is poised to leverage his extensive experience at Avance Clinical. His responsibilities will include developing and maintaining a proactive, solution-oriented team of regulatory experts, fostering a strong culture of compliance and customer-centricity, and spearheading regulatory operations for clinical trials. Alex’s role is crucial in ensuring that ‘ClinicReady’ and ‘GlobalReady,’ align with Avance’s commitment to supporting the development of products that significantly improve patient outcomes and quality of life.

Alex finds the integration of ‘ClinicReady’ and ‘GlobalReady’ concepts within Avance’s development strategies compelling. This approach not only enhances Avance’s domain expertise in scientific and regulatory field but promotes the development of innovative products that meet critical patient needs.

“I am thrilled to join Avance Clinical, an organization that stands at the forefront of innovation in the clinical research field,” Alex states. “I look forward to contributing to our clients’ success by navigating the regulatory landscape with precision and strategic foresight, ensuring that we continue to deliver solutions that advance patient care and improve quality of life.”

Please join us in welcoming Alex Kavros to the Avance Clinical team, where his expertise and leadership are anticipated to drive significant advancements in the biotech industry, reinforcing Avance’s position as a trailblazer in scientific and regulatory services.


About Avance Clinical

Avance Clinical is a full-service CRO for biotechs with a proven track-record for delivering clinical excellence in Australia, New Zealand, and North America. As the largest premium full-service CRO in Australia and North America, Avance Clinical specializes in delivering top-tier clinical trials that yield globally accepted data.

Award-winning CRO for Biotechs

Avance Clinical has been recognized for the fourth consecutive year by Frost & Sullivan in 2023, being awarded the Best Practices Customer Value Leadership for Biotech’s award, for its continuous exceptional performance.

Pre-clinical through to Phase I and Beyond

Avance Clinical offers pre-clinical consultancy services with their experienced ClinicReady team right through to Phase I and beyond clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes that are available in Australia and highly qualified sites and networks within the United States. With experience across more than 110 therapeutic indications, Avance Clinical can deliver world-class, high-quality, internationally accepted data suitable for FDA and EMA review.


Avance Clinical uses state-of-the-art technology and gold-standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, Zelta, Veeva and Medrio are just some of Avance Clinical’s technology partners.

Leave a Reply